Vascular patent for HealthLinx

HealthLinx [ASX: HTX] has been granted a US patent related to the company's vascular permeability program.

Licensed from the University of Virginia, the patent is related to the inhibition of the p21 activated kinase pathway as a treatment for disorders caused by aberrant vascular permeability.

It has widespread potential applications, including ischemia, stroke or burns.

The patent also forms part of the drug candidate CR014, a potential treatment for acute respiratory distress syndrome (ARDS) that the company is developing with the Canadian-based InSymbiosis.

No effective therapeutic treatments are available for the disease, which has a morbidity rate as high as 40 percent.

HealthLinx and InSymbiosis are preparing to embark on a preclinical development program for CR014.